Humalog Mix50 is a premixed suspensions consisting of 50% insulin lispro (fast-acting human insulin analogue) and 50% insulin lispro protamine suspension (intermediate acting human insulin analogue). The rapid onset and early peak of activity of Humalog itself allows Humalog Mix50 to be given very close to mealtime. The duration of action of the insulin lispro protamine suspension (BASAL) component of Humalog Mix 50 is similar to that of a basal insulin (NPH).
The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. As with all insulin preparations, the duration of action of Humalog Mix50 is dependent on dose, site of injection, blood supply, temperature, and physical activity.
Insulin requirements may be reduced in the presence of renal impairment. Insulin requirements may be reduced in patients with hepatic impairment due to reduced capacity for gluconeogenesis and reduced insulin breakdown. Insulin requirements may be increased during illness or emotional disturbances. Adjustment of dosage may also be necessary if patients undertake increased physical activity or change their usual diet.
Therapeutic indications – Israel
Humalog Mix50 is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
מסגרת הכללה בסל: התרופה האמורה תינתן לטיפול בחולי סוכרת.
Method of administration
The dosage should be determined by the physician, according to the requirement of the patient. Humalog Mix50 may be given shortly before meals. When necessary, Humalog Mix50 can be given soon after meals. Humalog Mix50 should only be given by subcutaneous injection. Under no circumstances should Humalog Mix50 be given intravenously. Subcutaneous administration should be in the upper arms, thighs, buttocks, or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a month. After injection, the site of injection should not be massaged.
Hypersensitivity to insulin lispro or to any of the excipients. Hypoglycaemia
Humalog Mix25 and Humalog Mix 50 KwikPen, Ministry of Health approved in September 2011.